Neurobalin Capsule 300 Milligrams (Pregabalin)
Pregabalin 300mg
Hard capsule · Prescription medication
White Life Sciences Co., Ltd.
MFDS item code 202009425 · Approved 2020.12.31
This product's status changed to Expired on 2025.12.31. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures
This medication is used to relieve peripheral and central neuropathic pain in adults. It is also utilized as an adjunct for partial seizures with or without secondary generalized symptoms in epilepsy patients. Additionally, it is effective in alleviating pain caused by fibromyalgia. It is widely used for the treatment of various nerve and muscle-related symptoms.
This medicine is administered orally as pregabalin, with the total daily dose divided into 2 doses, with or without food. Because this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (Refer to section ‘5. Patients with renal impairment’) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300mg/day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals up to a maximum of 600mg/day. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300mg/day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600mg. If the target daily dose is not tolerated, dose reduction may be considered. (Refer to section ‘4. Discontinuation of treatment’) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300mg/day after 1 week. If necessary, it may subsequently be increased at 7-day intervals up to a maximum of 600mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300mg∼450mg/day. The starting dose is 75mg twice daily (150mg/day), and based on efficacy and tolerability, it may be increased to 150mg twice daily (300mg/day) within 1 week. For patients who do not experience sufficient benefit at a dose of 300mg/day, the dose may be increased to 225mg twice daily (450mg/day) within 1 week. Clinical studies have also been conducted at a dose of 600mg/day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450mg/day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, when discontinuing this medicine, it should be tapered gradually over a period of at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medicine is excreted primarily by the kidneys unchanged. Because the clearance of this medicine is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. *: For females, multiply the result obtained using the above calculation by 0.85. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosing based on renal function Creatinine clearance (CLcr), (mL/min) / Total daily dose of pregabalin a / Dosing regimen / Starting dose (mg/day) / Maximum dose (mg/day) ≥60 / 150 / 600 / BID or TID ≥30-<60 / 75 / 300 / BID or TID ≥15-<30 / 25-50 / 150 / QD or BID <15 / 25 / 75 / QD Supplemental dose after hemodialysis / 25 / 100 / Single dose TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = once daily a: The total daily dose (mg/day) should be divided as specified under the dosing regimen. b: The supplemental dose refers to an additional dose administered as a single dose. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly patients (65 years of age or older) Dose reduction may be necessary in elderly patients with impaired renal function.
Children under 12 years of age: Use is not recommended because sufficient safety and efficacy data are not available. Adolescent patients aged 12∼17 years: Use is not recommended because sufficient safety and efficacy data are not available.
This medication contains an anticonvulsant component, and while taking it, there may be mental changes such as suicidal thoughts, suicidal behavior, or depression, which should be closely monitored for any changes in symptoms. Patients allergic to pregabalin or any components of this medication, as well as those with certain genetic lactose intolerance, should not take this medication. Diabetic patients may require adjustment of blood sugar control medication dosage due to weight gain, and if symptoms of edema appear, consumption should be stopped immediately. Elderly patients should be cautious as dizziness or drowsiness may increase with this medication, and one should be careful until accustomed to its effects. This medication may cause transient blurred vision or changes in eyesight, and consultation with a doctor is necessary if symptoms appear. Abrupt cessation may result in withdrawal symptoms such as insomnia, headache, nausea, and anxiety; therefore, dosage should be gradually adjusted according to a doctor's instructions. Patients with a history of substance abuse should take this medication carefully due to the risk of misuse or abuse, and signs of drug dependence should be closely monitored. Patients with impaired kidney function may require dose adjustments, and those with heart disease should use caution while taking the medication. Co-administration with opioid analgesics may increase the risk of central nervous system depression; therefore, caution is advised, particularly in patients with respiratory disease or kidney impairment, as there is a risk of severe respiratory depression necessitating dosage adjustments. In early pregnancy, there may be a risk of congenital malformations to the fetus, so pregnant women should not take this medication unless in special circumstances, and women of childbearing age should utilize effective contraceptive methods. Breastfeeding women should consult with a doctor about stopping breastfeeding or discontinuing the medication, as this medication can pass into breast milk and affect the baby. Before driving or operating dangerous machinery, it is necessary to verify whether this medication causes dizziness or drowsiness. If severe rash, swelling, or difficulty breathing occurs while taking this medication, one should stop taking it immediately and inform healthcare personnel. In case of overdose, symptoms may include drowsiness, confusion, depression, seizures, and immediate medical treatment should be sought, and blood dialysis may be performed if necessary. Children and the elderly should keep this medication in a safe place out of reach. This medication has few drug interactions; however, caution is warranted when used in conjunction with central nervous system depressants as effects may be enhanced.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent exposure to air or moisture. Additionally, it is important to store it at a cool temperature between 15 degrees and 30 degrees Celsius to maintain its efficacy.
A hard capsule with a reddish-brown upper part and white lower part containing a white powder that is white or light yellow.
30 capsules/bottle, 100 capsules/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Pregabalin 300mg
Hard capsule · Prescription medication
White Life Sciences Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.